Nepsis Inc. Trims Position in United Therapeutics Corporation $UTHR

Nepsis Inc. lowered its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 7.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 44,416 shares of the biotechnology company’s stock after selling 3,356 shares during the period. United Therapeutics makes up 5.9% of Nepsis Inc.’s holdings, making the stock its biggest holding. Nepsis Inc.’s holdings in United Therapeutics were worth $18,620,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of UTHR. F m Investments LLC grew its stake in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after purchasing an additional 33 shares in the last quarter. HB Wealth Management LLC raised its stake in United Therapeutics by 2.9% during the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 35 shares in the last quarter. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Park Avenue Securities LLC grew its position in shares of United Therapeutics by 1.7% in the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after acquiring an additional 39 shares in the last quarter. Finally, Coldstream Capital Management Inc. increased its holdings in shares of United Therapeutics by 2.0% in the 2nd quarter. Coldstream Capital Management Inc. now owns 2,145 shares of the biotechnology company’s stock valued at $616,000 after acquiring an additional 43 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $483.23 on Friday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99. The stock’s fifty day moving average is $483.94 and its 200-day moving average is $401.49. The firm has a market capitalization of $20.81 billion, a price-to-earnings ratio of 18.31, a price-to-earnings-growth ratio of 2.55 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.39 earnings per share. Analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on UTHR shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. UBS Group increased their price objective on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Finally, HC Wainwright upped their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $509.50.

Insider Buying and Selling

In related news, Director Jan Malcolm sold 50 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $512.12, for a total transaction of $25,606.00. Following the sale, the director owned 420 shares of the company’s stock, valued at $215,090.40. The trade was a 10.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $485.43, for a total value of $4,029,069.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $17,854,600.83. The trade was a 18.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 608,514 shares of company stock worth $284,376,421. Company insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.